Sophia Genetics SA (SOPH): Price and Financial Metrics
GET POWR RATINGS... FREE!
SOPH Stock Price Chart Interactive Chart >
SOPH Price/Volume Stats
| Current price | $4.45 | 52-week high | $19.80 |
| Prev. close | $4.49 | 52-week low | $3.99 |
| Day low | $4.31 | Volume | 18,573 |
| Day high | $4.54 | Avg. volume | 82,867 |
| 50-day MA | $6.58 | Dividend yield | N/A |
| 200-day MA | $12.53 | Market Cap | 281.85M |
Sophia Genetics SA (SOPH) Company Bio
Sophia Genetics SA, a cloud-based software-as-a-service platform that enables healthcare institutions to get insights from their data. The company offers SOPHiA DDM for solid tumors. Sophia Genetics SA was founded in 2012 and is based in Saint-Sulpice, Switzerland.
Latest SOPH News From Around the Web
Below are the latest news stories about SOPHiA GENETICS SA that investors may wish to consider to help them evaluate SOPH as an investment opportunity.
SOPHiA GENETICS Launches New Deep Learning Capabilities to Support the Detection of Homologous Recombination DeficienciesSOPHiA GENETICS (Nasdaq: SOPH), a leader in Data-Driven Medicine, announced today the launch of their SOPHiA DDM Homologous Recombination Deficiency (HRD) Solution, opening new doors for cancer research. The application provides a unique approach for molecular cancer testing by combining the identification of HRD-causing mutations with the analysis of HRD-induced genomic instability across the whole genome of tumor samples. |
First Japanese Institution to Utilize SOPHiA GENETICS'' Myeloid Plus SolutionBOSTON , LAUSANNE, Switzerland , and HIROSHIMA, Japan , Feb. 22, 2022 /CNW/ -- SOPHiA GENETICS (NASDAQ: SOPH ), today announced an agreement with Hiroshima University, one of the top public universities in Hiroshima City, Japan , to support their molecular profiling by next-generation sequencing (NGS) in investigating the pathogenic variants causing different blood cancer disorders. Hiroshima University is home to one of the largest university research institutes in the field of radiation biomedical science in Japan. With NGS for myeloid testing not widely available in Japan , a group of Hiroshima University researchers tapped the SOPHiA DDM Platform to assist with the clinical utility of NGS tests for myeloid malignancies. Hiroshima University aimed to establish a framework where the N... |
First Japanese Institution to Utilize SOPHiA GENETICS' Myeloid Plus SolutionSOPHiA GENETICS (Nasdaq: SOPH), today announced an agreement with Hiroshima University, one of the top public universities in Hiroshima City, Japan, to support their molecular profiling by next-generation sequencing (NGS) in investigating the pathogenic variants causing different blood cancer disorders. |
SOPHiA GENETICS to Announce Fourth Quarter and Full Year 2021 Financial Results on March 15, 2022BOSTON and LAUSANNE, Switzerland, Feb. 16, 2022 (GLOBE NEWSWIRE) -- SOPHiA GENETICS SA (Nasdaq: SOPH), a leader in data-driven medicine, today announced it will release its financial results for the fourth quarter and full year 2021 before U.S. markets open on Tuesday, March 15, 2022. SOPHiA will host a conference call and live webcast to discuss its financial results as well as business outlook beginning at 8:30 a.m. Eastern Time / 2:30 p.m. Central European Time. |
SOPHiA GENETICS (NASDAQ:SOPH) Is In A Good Position To Deliver On Growth PlansJust because a business does not make any money, does not mean that the stock will go down. For example, although... |
SOPH Price Returns
| 1-mo | -41.52% |
| 3-mo | -64.26% |
| 6-mo | -69.20% |
| 1-year | N/A |
| 3-year | N/A |
| 5-year | N/A |
| YTD | -68.44% |
| 2021 | N/A |
| 2020 | N/A |
| 2019 | N/A |
| 2018 | N/A |
| 2017 | N/A |
Loading social stream, please wait...